Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | TNKS | O95271 | 4/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | CASR | P41180 | 6/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095872 | 0.89 | CCR5 (0.37) | CCR5CASRRORCTACR1CYP2D6 | |
| SCHEMBL1096488 | 0.87 | CCR5 (0.39) | CCR5CASRRORCTACR1 | |
| SCHEMBL1096960 | 0.86 | CASR (0.41) | CCR5CASRRORCCYP2D6 | |
| SCHEMBL1095663 | 0.84 | CCR5 (0.40) | CCR5CASR | |
| SCHEMBL1095814 | 0.84 | CCR5 (0.42) | CCR5TNKSTNKS2CASRUSP30 | |
| SCHEMBL1095781 | 0.84 | CCR5 (0.39) | CCR5TNKSTNKS2PARP1CASR | |
| SCHEMBL4110113 | 0.84 | CCR5 (0.41) | CCR5CASRRORCTACR1 | |
| SCHEMBL1096628 | 0.83 | CASR (0.39) | CCR5CASRUSP30TACR1CYP2D6 | |
| SCHEMBL4101486 | 0.83 | CCR5 (0.38) | CCR5CASRRORCCYP2D6 | |
| SCHEMBL1096487 | 0.83 | CASR (0.40) | CCR5CASRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2085383-A1 | PIPERIDINE DERIVATIVES OR SALTS THEREOF | Astellas Pharma Inc. (JP) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | CCR5 542/4885TNKS 3089/4885TNKS2 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.